The cytotoxic farnesyl transferase inhibitor BMS-214662 has been shown to potently induce mitochondrial apoptosis in primitive CD34 þ chronic myeloid leukaemia (CML) stem/ progenitor cells. Here, to enhance the BMS-214662 apoptotic effect, we further targeted the extracellular signal-regulated kinase (ERK) pathway, downstream of BCR-ABL, by treating CD34 þ CML stem/progenitor cells with a highly selective adenosine triphosphate (ATP) non-competitive MEK inhibitor, PD184352. PD184352 increased the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34 þ CML cells. Compared with BMS-214662, after combination treatment we observed inhibition of ERK phosphorylation, increased Annexin-V levels, caspase-3, -8 and -9 activation and potentiated mitochondrial damage, associated with decreased levels of anti-apoptotic BCL-2 family protein MCL-1. Inhibition of K-RAS function by a dominant-negative mutant resulted in CML cell death and this process was further enhanced by the addition of BMS-214662 and PD184352. Together, these findings suggest that the addition of a MEK inhibitor improves the ability of BMS-214662 to selectively target CML stem/progenitor cells, notoriously insensitive to tyrosine kinase inhibitor treatment and presumed to be responsible for the persistence and relapse of the disease.
Introduction
Chronic myeloid leukaemia (CML) is a clonal disorder of haemopoietic stem cells characterized by the enhanced production of myeloid cells as a consequence of the reciprocal translocation t(9;22). 1 As a result of the translocation, the BCR-ABL oncogene encodes for a constitutively active tyrosine kinase (TK) and imatinib mesylate (IM) is a TK inhibitor used as conventional treatment for CML. 2, 3 Although IM treatment results in achievement of complete cytogenetic response only a minority of patients achieve complete molecular response. 4, 5 Persistence of BCR-ABL þ stem cells with repopulating capacity in CML patients in prolonged complete cytogenetic response after 5 years of IM treatment, indicates that patients remain at risk of relapse on drug discontinuation or through acquisition of IM resistance. 6 The second-generation TK inhibitors, nilotinib and dasatinib, are significantly more potent ABL inhibitors than IM, but they are still not able to target the most primitive CML stem cells. [7] [8] [9] [10] [11] Recently, the 'non-randomized stop IM' trial has shown that 61% of CML patients that discontinued IM after achieving complete molecular remission relapsed. 12 Recently, new therapeutic targets are actively being sought, mainly among the BCR-ABL downstream pathway proteins. Among them the RAS signalling pathway has a pivotal role. Localization of RAS to the cell membrane, where it is capable of activating downstream signalling events, requires modification by intracellular farnesyl transferases (FT). BMS-214662 is a cytotoxic FT inhibitor (FTI) designed to inhibit farnesylation of RAS and able to induce apoptosis in both proliferating and quiescent CML stem/progenitor cells in chronic phase (CP) samples. 13, 14 We have shown that BMS-214662, in addition to its activity as a FTI, is able to induce apoptosis through a different mechanism of action. 15 Recent studies have demonstrated that BMS-214662 has a significantly higher potency to reduce quiescent CML stem cells through the induction of apoptosis, as compared with other FTIs, such as BMS-225975 or lonafarnib. [14] [15] [16] Additional targeting of MEK has been shown to further increase the activity of IM and dasatinib in BCR-ABLpositive cell lines. 17, 18 The first MEK inhibitor to enter clinical trials is PD184352. It is a highly potent and selective adenosine triphosphate non-competitive inhibitor of both MEK isoforms (MEK1 and MEK2). 19, 20 In this study, we used a combination of the MEK inhibitor PD184352 with BMS-214662 to increase the effect of BMS-214662 in a CML blast crisis cell line, K562 and in primary CP CML stem/progenitor cells (CD34 þ , CD34 þ 38À).
Materials and methods

Reagents
BMS-214662 was obtained from Bristol-Myers Squibb (Princeton, NJ, USA). PD184352 (CI-1040) was chemically synthesized in-house based on the published structure of the drug. U0126 was from Calbiochem (Chemicals Ltd, Nottingham, UK). All reagent grade chemicals were purchased from Sigma-Aldrich Company Ltd (Poole, UK), unless otherwise stated.
Isolation and culture of CD34 þ cells and culture of K562 cell line Fresh leukapheresis or peripheral blood samples were obtained with written informed consent from patients with CP CML at diagnosis previous treatment or non-CML donors. Samples were enriched for CD34 þ cells using CliniMACS (Miltenyi Biotec Inc., Auburn, CA, USA) according to the manufacturer's instructions. Samples were cultured as previously described.
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CD34 þ 38-population was isolated as previously described. 15 After treatment for 24 h as indicated, CD34 þ cells were set up in long-term culture-initiating cell assays as previously described. 14 The Ph þ blast crisis K562 cell line was maintained in 10% FCS/RPMI 1640 medium (Invitrogen, Paisley, UK).
Flow cytometry (fluorescence-activated cell sorting) and synergy analysis Cells were stained with Annexin-V fluorescein isothiocyanate or Annexin-V APC and 7-amino-actinomycin D (BD Via-Probe) in Annexin-V binding buffer (everything from Becton Dickinson, Oxford, UK). The level of active caspase-3 was assessed by intracellular staining. Cells were re-suspended in 'Fix and Perm' (Merck, Whitehouse Station, NJ, USA). The primary anticaspase-3-PE antibody (Becton Dickinson) was incubated for 1 h. In all, 10 mM FMK-ZVAD (Bachem, St Helens, UK) was added to the culture 2 h before treatment with BMS-214662 and PD184352. Decrease in mitochondrial membrane potential was detected using 50 nM TMRE (Cell Technology, San Diego, CA, USA) for 20 min at 37 1C. Fluorescence-activated cell sorting analysis was performed using the FACSCanto Flow Cytometer (Becton Dickinson). Data analysis was performed with FACSDiva (Becton Dickinson) or FlowJo (Tree Star, Ashland, OR, USA) software. Drug synergy for PD184352 and BMS-214662 was determined after 24 h culture using K562 viable cell gate in Annexin-V and 7-amino-actinomycin D measurement and the median-effect method of Chou and Talalay 22 and analyzed using CalcuSyn software (Biosoft, Cambridge, UK).
K562 transfection and lentiviral infection
The K-RAS-N17 dominant-negative mutant plasmid was obtained from Dr D Matallanas-Gomez. 23 K562 cells were transfected using Amaxa nucleofection with cell-line Nucleofector Kit V (Lonza Group Ltd, Cologne, Germany) as per the manufacturer's instructions. In all, 5 mg of DNA from K-RAS N17 plasmid was transfected. RAS activity was detected using a RAS activation assay (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Efficiency of the pull-down assay was shown by using positive and negative controls guanosinethiotriphosphate (GTPgS) and guanine nucleotide-binding protein (GDP), respectively). DN-MEK1 plasmid was obtained from Professor Chris Marshall. 24 For retroviral infection, virus was produced by transfection of Phoenix cells with DN-MEK1 and control empty plasmids by the calcium phosphate method. Virus-containing supernatant was collected 48 and 72 h following transfection, filtered through a 0.45-mm filter and added to K562 cells. Polybrene was added to a final concentration of 8 mg/ml. Infected K562 cells were selected in 5 mg/ml puromycin.
Western blotting
Western blotting was performed as previously described. 15 Incubation at 1:500 (p-ERK, p-STAT5, STAT5 and MCL-1) or 1:1000 (caspase-8, -9, PARP, HDJ2, extracellular signalregulated kinase (ERK) and glyceraldehyde 3-phosphate dehydrogenase) dilution of primary antibodies was carried out at 4 1C overnight, and with secondary antibody (1:5000 anti-rabbit horseradish peroxidase) for 1 h at room temperature and then the blots were developed with the ECL kit (Immun-Star WesternC; Bio-Rad, Hemel Hempstead, UK) according to the manufacturer's instructions. All the above antibodies were purchased from New England Biolabs (Hitchin, UK). Anti-RAS (RAS10, Millipore) was used to show RAS pull down.
Statistical analysis
Statistical analyses were performed using the Student's t-test. A level of Pp0.05 was taken to be statistically significant. A level of Pp0.005 was taken to be highly statistically significant.
Results
Co-treatment with PD184352 and BMS-214662 synergistically enhances apoptosis in K562 cell line BCR-ABL-positive K562 cells are sensitive to combination treatment with dasatinib and MEK inhibitors. 17 Therefore, we investigated the activity of BMS-214662 in combination with PD184352 in K562 cells and whether there are synergistic or additive effects between these two drugs. Treatment of K562 cells with increasing concentrations of BMS-214662 for 24 h resulted in only a modest increase in early apoptosis. However, co-administration of 5 mM PD184352 with BMS-214662 resulted in significantly enhanced early apoptosis (P ¼ 0.008) (Figure 1a) . While an incomplete cleavage of PARP (the main target of the pro-apoptotic factor caspase-3) was still noticeable in the sample treated with BMS-214662 alone, the un-cleaved band completely disappeared after co-treatment with PD184352 ( Figure 1b) . In all, 5 mM PD184352 showed almost no effect on PARP cleavage, whereas it did have an effect at 10 mM, although not to the same extent as with the combination. To prove that PD184352 blocks the mitogen-activated protein kinase (MAPK) pathway, phosphorylation of ERK, the unique substrate of MEK, was measured (Figure 1b) . Addition of PD184352 inhibited phosphorylation. Only a mild decrease in p-ERK was detected using BMS-214662 alone, which likely affected MAPK signalling through inhibition of RAS farnesylation. These data support the findings that BMS-214662 target CML cells not entirely through its FTI activity as previously shown. 15 The STAT family proteins are among the downstream proteins highly activated by BCR-ABL. 25 Interestingly, strong inhibition of p-STAT5 on tyrosine 694Fthe major phosphorylation site by SRC kinases in K562 cells 26 Fwas observed after treatment with BMS-214662 ( Figure 1b ). Little decrease was observed when 5 mM PD184352 was added, whereas it was more evident with 10 mM PD184352. The combination with PD184352 and BMS-214662 showed a complete inhibition of STAT5 phosphorylation, presumably due mostly to BMS-214662 activity. We have recently shown that BMS-214662 induces mitochondrial apoptosis in CML stem/progenitor cells. 15 The mitochondrial anti-apoptotic protein MCL-1 is known to be constitutively activated by BCR-ABL, through activation of the RAS-RAF (rabbit fibrosarcoma protein)-MAPK pathway. 27 Downregulation of MCL-1 was seen as a result of treatment with BMS-214662, which was increased in combination with PD184352 ( Figure 1c ). PD184352 alone had no effect on MCL-1 levels. To further investigate the effect of the treatment on the apoptotic pathways, we investigated activation of caspase-8 and -9. We observed cleavage of caspase-9 after combination treatment with BMS-214662 and PD184352. Neither of these drugs alone caused cleavage of caspase-9 ( Figure 1c ). Analysis of caspase-8 also revealed cleavage after combination treatment ( Figure 1c) .
Finally, we investigated synergism between BMS-214662 and PD184352 on K562 cells using the CalcuSyn software program (Biosoft). Combination index at IC50 was 0.357 for doses ranging from 125 to 2000 nM of BMS-214662 and from 2.5 to 40 mM of PD184352, mixed in a constant ratio of 20:1 (Figure 1d ), indicating that this combination was synergistic.
Taken together, these data indicate that exposure of K562 to a combination of BMS-214662 and PD184352 caused a demonstrable enhancement in apoptosis. This is presumably as a result of the apoptotic effect of BMS-214662, which is potentiated by the abrogation of MAPK activation.
MEK inhibition with K-RAS N17 and DN-MEK enhances BMS-214662/ PD184352-induced apoptosis in K562 cells
To confirm the involvement of the RAS pathway in BMS-214662-induced apoptosis, we blocked the function of the K-RAS protein by transfecting a K-RAS N17 dominant-negative mutant into K562 cells (Figure 2a ). This particular RAS mutant, with a substitution of serine 17 by asparagine (RAS N17), competes with the wild-type form of RAS. 23 BMS-214662 treatment alone resulted in a reduction in cell viability in the K-RAS N17 mutant compared with the mock-treated cells (Figure 2ai ). Furthermore, the combination of BMS-214662 and PD184352, used at sub-lethal concentrations, resulted in significantly greater reduction of viable cells in the K-RAS N17 mutant compared with the mock-treated cells. This confirms the importance of RAS inhibition to the combination effect of BMS-214662 with MAPK inhibition. RAS pull-down assay was used to demonstrate the reduction of active RAS in K-RAS N17 transfected cells in comparison with the mock-treated control (Figure 2aii ). Finally, K562 cells were retrovirally infected with the dominant-negative form of MEK1 (DN-MEK1) 24 and treated with BMS-214662 or PD184352 or the combination (Figure 2b BMS-214662 compared with cell lines, which required high concentrations of the drug to enter apoptosis (IC50 for primary CML: 62.5 nM; IC50 for K562 cells: 2 mM).
14,28 CML CD34 þ cells were then treated with different concentrations of BMS-214662 alone or in combination with of PD184352 (n ¼ 3) (Figure 3bii ). Treatment combination with the MEK inhibitor significantly decreased the viable cell count compared with BMS-214662 alone, particularly when high concentrations of BMS-214662 were added (P ¼ 0.01, P ¼ 0.009, P ¼ 0.0006). In all, 10 mM PD184352 alone had a minor effect on CD34 þ cells.
The enhanced effect of PD184352 on BMS-214662-induced apoptosis was then examined in CD34 þ CML cells from patients in CP (n ¼ 3) (Figure 3ci ). Co-administration of 10 mM PD184352 with 250 nM BMS-214662 for 24 h resulted in a significant increase in early apoptosis (P ¼ 0.002). Addition of 10 mM of the equally effective MEK inhibitor U0126 enhanced the apoptotic effect of BMS-214662 in a similar manner (P ¼ 0.007), proving that inhibition of the MAPK pathway, in particular of MEK, leads to enhancement of BMS-214662-induced apoptosis (Figures 3ci and ii) . Western blotting was performed to analyze cleavage of the apoptotic marker PARP after treatment of CD34 þ CML cells (Figure 4a ). Although BMS-214662 alone caused cleavage of PARP after 24 h, a further increase in PARP cleavage was observed in the combination treatment with PD184352. We then investigated the phosphorylation of ERK and found it was blocked after 24 h of treatment with PD184352. As we observed in K562, a milder effect was detected after treatment with BMS-214662, supporting the previous indication that BMS-214662 has weak FTI activity in CML cells (Figure 3a) . The decrease in p-ERK observed with the combination therapy was likely to be caused mainly by the addition of PD184352.
In K562, we detected a decrease in p-STAT5 after treatment with BMS-214662, which was further enhanced with the addition of PD184352. Densitometry analysis relative to glyceraldehyde 3-phosphate dehydrogenase loading control (data not shown) showed that in CD34 þ cells both the levels of total STAT5 and p-STAT5 decreased after combination treatment with BMS-214662 and PD184352, likely due to cell death. A similar effect was observed when a time course treatment with the drugs alone or in combination was performed. After 6, 8 and 12 h no effect was detected, but after 24 h there was a clear decrease in p-STAT5 in the combination treatment (Figure 4b ). Finally, we analyzed the level of MCL-1 and the cleavage of caspase-9 in CML CD34 þ cells. We found that a decrease in MCL-1 levels was detected after 24 h treatment with BMS-214662 and PD184352 (Figure 4a ), although because of reduction in glyceraldehyde 3-phosphate dehydrogenase at this time point the change was not dramatic. Increase in the level of cleaved caspase-9 was detected after treatment with BMS-214662 alone and no further increase was observed in the drug combination.
To additionally characterize the apoptotic effects of the combination of BMS-214662 and PD184352, we examined changes in mitochondrial membrane potential. We have previously shown that BMS-214662 alone causes a decrease in mitochondrial membrane potential. 15 Similar results were obtained in this study (Figure 4c ). When PD184352 was added, the mitochondrial membrane potential further decreased, suggesting that the combination treatment caused a more effective activation of the mitochondrial apoptotic pathway. All the samples used for this study were from patients at diagnosis and before therapy and detailed information of CML patients/samples used for this study is included (Figure 4d ).
Combination treatment with BMS-214662 and MEK inhibitors leads to enhanced activation of caspase-3 in CD34 þ and CD34 þ 38-populations
In CD34 þ CML cells caspase-3 activation was detected with 250 nM BMS-214662, but the co-addition of either PD184352 or U0126 greatly increased the effect (Po0.005). PD184352 or U0126 alone did not induce activation of caspase-3 ( Figure 5a ). Parallel studies were performed in CD34 þ CML cells treated with BMS-214662 and PD184352 exposed to the pan-caspase inhibitor FMK-ZVAD (Figure 5b ). We observed that by inhibiting caspases the apoptosis measured by caspase-3 activation was rescued, both with BMS-214662 alone and in combination with PD184352.
CD34 þ 38-cells are the most primitive fraction within bulk CD34 þ cells and have previously been shown to be predominantly quiescent. 29 Standard TK inhibitors are ineffective in eradicating CML, probably due to their incapacity to target this sub-population. Here, CD34 þ 38 þ cells were separated from CD34 þ 38-(o5% of total CD34 þ cells) CML cells by fluorescence-activated cell sorting. We treated the CD34 þ 38 þ and CD34 þ 38 -CML cells with 250 nM of BMS-214662, 10 mM U0126, or the combination (Figure 5c ). As expected, after 24 h an increase in activation of caspase-3 was detected in both populations after treatment with BMS-214662 alone, although the more mature cells were more sensitive (18.9 and 29.6%, respectively). U0126 alone did not have any effect on the cells (1 and 2.6%, respectively). A dramatic increase in apoptosis was detected when BMS-214662 was combined with U0126, both in CD34 þ 38 þ and CD34 þ 38 -CML cells (32 and 41%, respectively) (n ¼ 1, because of limitation of sample MEK inhibition and BMS-214662-mediated apoptosis F Pellicano et al availability). IM treatment only caused a mild increase in apoptosis in CD34 þ 38 þ but not in CD34 þ 38 -(6.2 and 1.1%, respectively). Taken together these experiments confirmed that apoptosis induced by a combination of BMS-214662 and PD184352 leads to a strong activation of the caspasemediated apoptotic pathway.
Combination treatment with BMS-214662 and MEK inhibitors is relatively selective for CML versus normal stem/progenitor cells Activation of caspase-3 was compared between CML and normal CD34 þ cells. BMS-214662 was selective in inducing apoptosis in CML CD34 þ cells after 24 h of treatment (Figure 6a) . Combination of PD184352 and BMS-214662 caused a far greater increase in caspase-3 activation in CML (24.1%) than in normal cells.
To measure the effect of combination treatment on the most primitive CML cells, we performed long-term culture-initiating cell assays with CML and normal CD34 þ cells after 24 h of treatment with PD184352, BMS-214662 or BMS-214662 plus PD184352 (Figure 6b) . Surprisingly, in CML CD34 þ cells, the addition of PD184352 alone reduced long-term cultureinitiating cell compared with the no drug control. Similarly, BMS-214662 reduced the number of colonies compared with PD184352 alone, but the strongest effect on long-term Pericardial and pleural effusion within 4 weeks of starting IM. Switch to nilotinib but severe skin reaction. Now CCR on dasatinib by 6 months.
Treatment with IM 800mg was stopped twice due to pancytopenia and hepato-toxicity. Switch to dasatinib initially 20mg daily. Increased to 50mg and 100mg daily. Achieved MMR, CMR not achieved to date. culture-initiating cell was observed after the treatment with the combination of PD184352 and BMS-214662. In normal CD34 þ cells, we observed a similar but weaker trend and the decrease in the number of colonies was not as marked, suggesting that the combination of PD184352 and BMS-214662 is relatively selective for CML versus normal stem cells (n ¼ 1, because of limitation of sample availability).
Discussion
In this study, we investigated the activity of BMS-214662 and PD184352 in targeting the CML blast crisis cell line, K562, and primary CD34 þ CML stem/progenitor cells. CML is one of the most extensively studied malignancies and serves as a paradigm for targeting molecular pathogenic events. A single genetic abnormality allows attention to be focused on deregulated BCR-ABL signal transduction and the pivotal role of BCR-ABL downstream MAPK proteins in intracellular signalling makes them attractive therapeutic targets.
We have previously shown that the FTI BMS-214662 selectively targets quiescent CML stem cells, by a mechanism that is not solely through inhibition of farnesylation of RAS, which BMS-214662 was specifically designed to inhibit. 15 The unique ability of BMS-214662 to target quiescent CML stem/progenitor cells is partially explained by aberrant activation of CDK2 and an upregulation of PKCb, in addition to FT inhibition. These changes result in activation of the intrinsic apoptotic pathway. 15 Here, we have focused on targeting the MAPK pathway in CML cells, by using both a specific MEK inhibitor and the FTI BMS-214662. BMS-214662, compared with FTIs BMS-225975 and lonafarnib, did not show as marked FTI activity, despite its ability to target primitive stem/progenitor cells. We hypothesized that combining BMS-214662 with an additional inhibitor of the MAPK pathway may improve its activity, either as a FTI or through another mechanism. Previous studies have shown that PD184352 interacts synergistically with TK inhibitors to induce apoptosis in BCR-ABLexpressing cells. 17, 18 Therefore, we used PD184352 in combination with BMS-214662. The data presented suggest that the combination of BMS-214662 with the MEK inhibitors PD184352 or U0126 induces a greater level of apoptosis in K562 and CD34 þ CML cells than BMS-214662 alone. We confirmed enhanced apoptosis by 24 h of combination treatment using various methods, including Annexin-V in combination with 7-amino-actinomycin D, measurement of active caspase-3, -8, -9 and PARP. In K562, we also detected a strong decrease in the expression of the anti-apoptotic protein MCL-1, which has previously been implicated in the pathogenesis of CML and cleavage of caspase-8. 30, 31 Taken together, these data suggest, that combination treatment affects the mitochondrial pathway of apoptosis in CML cells. It is still not clear whether cleavage of caspase-8 was a downstream effect of active caspase-3 or caused by activation of a parallel non-mitochondrial apoptotic pathway. In K562, we found a decrease in p-STAT5 on Tyrosine 694 after treatment with BMS-214662. Interestingly, p-STAT5 downregulation was seen also in CD34 þ CML cells, but together with decreased level in total STAT-5. Similarly for p-ERK, the decrease in phosphorylation detected was likely to be caused solely by PD184352, because no additional effect was seen after the combination of the two drugs or BMS-214662 alone. These results suggest the possibility of a difference in drug responses between K562 and primary CML CP cells. In fact, our previous studies suggested that CD34 þ CML cells are more sensitive to BMS-214662 than K562 cells. 14, 28 This difference may be due to the fact that K562 is a blast crisis cell line, whereas the CD34 þ cells used here were CP. In addition, K562 cells have aberrant copy numbers of BCR-ABL, which is likely to provide stronger survival signalling. We have previously shown that, although inducing mitochondrial apoptosis, BMS-214662 does not affect the protein level of the BCL-2 family members, including BCL-2, MCL-1, BIM and BCLXL. Here, we have shown that the addition of PD184352 to BMS-214662 blocks the expression of the anti-apoptotic protein MCL-1 in the CML cell line (only modestly in primary CML cells), whereas the two drugs alone do not have a significant effect. It is unlikely that increased potency of BMS-214662 in inducing apoptosis in primary CML cells after the addition of PD184352 is caused solely by the mild inhibition of MCL-1. CML cells express MCL-1 in a constitutive manner and dominant-negative RAS mutant, RAS-N17, reversed BCR-ABLdependent MCL-1 activity in Ba/F3 cells. 27 The role that MCL-1 has in the survival and accumulation of leukaemic cells in CML patients is still unclear.
Finally, inhibition of the MAPK pathway by using DN forms for RAS and MEK together with the combination of the drugs, further decreased cell viability. Interestingly, when either DN form was used with BMS-214662 this did not mirror the effect of PD184352 when combined with BMS-214662, suggesting that full inhibition of the pathway, likely given only by PD184352, is necessary to see an enhanced effect on cell death.
Results of this work suggest that inhibition of the RAS-MEK-ERK pathway by MEK inhibitors increases the apoptotic effect of BMS-214662 in CD34 þ CML stem/progenitor cells. BMS-214662 does not appear to have a strong FTI activity in CML primary cells and it is possible that the addition of a second agent targeting the RAS pathway potentiates its ability to inhibit this signalling cascade, leading to the inhibition of the protective factor MCL-1 and consequently causing enhanced apoptosis. It is also plausible that the addition of a MEK inhibitor may potentiate the off target effects of BMS-214662, independently from its FTI activity. However, until the exact mechanism of action of BMS-214662 is understood this remains speculative. This study suggests an important role for potent MEK inhibitors in the treatment of CML.
